Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 19 clinical trials
Cisplatin+Pembrolizumab+RT in Vulvar Cancer

This research is being done to see how well the combination of a standard of care drug, investigational drug, and radiation therapy work against unresectable vulvar squamous cell carcinoma. This research study involves the following: Cisplatin (standard of care drug) Pembrolizumab (investigational drug) Radiation Therapy (standard of care intervention)

neutrophil count
metastasis
vulvar carcinoma
erythropoietin
metastatic squamous cell carcinoma
  • 0 views
  • 19 Feb, 2024
  • 1 location
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2

Embedded within the Master Study are individual drug substudies. Investigational Drug Sub-study A: Brigatinib

experimental drug
nf2 gene
glioma
multiple meningiomas
neurofibroma
  • 0 views
  • 19 Feb, 2024
  • 2 locations
Oral EPI-7386 in Patients With Metastatic Castration-Resistant Prostate Cancer

This is a phase I, clinical research study of EPI-7386, an investigational drug being studied as a treatment for patients with prostate cancer. All patients in the study will receive EPI-7386. Since this is the first study of EPI-7386 in humans, there is no information about how it affects people …

bone scan
progressive disease
diphosphonates
bone lesion
metastasis
  • 0 views
  • 19 Feb, 2024
  • 5 locations
Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers

This clinical trial is studying two immunotherapy drugs (nivolumab and ipilimumab) given together as a possible treatment for INI1-negative tumors.

neutrophil count
monoclonal antibodies
ipilimumab
epithelioid sarcoma
cancer therapy
  • 0 views
  • 19 Feb, 2024
  • 1 location
Ipatasertib + Atezolizumab to Prevent Recurrence in TNBC

The purpose of this study is to determine if a combination of two drugs ipatasertib and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulating tumor DNA in the blood. This research study involves the following investigational drugs: Ipatasertib Atezolizumab

invasive breast cancer
atezolizumab
immunostimulant
absolute lymphocyte count
lymphadenectomy
  • 0 views
  • 19 Feb, 2024
  • 1 location
Ibrutinib + Venetoclax in Untreated WM

This study evaluates the safety and efficacy of Ibrutinib combined with Venetoclax (IVEN) in the treatment of adults diagnosed with Waldenstrom's macroglobulinemia (WM) cancer with a specific MYD88 gene mutation. This research study involves an experimental drug combination of targeted therapies. The names of the study drugs involved in this …

platelet transfusion
waldenstrom's macroglobulinemia
plasmapheresis
neutrophil count
absolute neutrophil count
  • 0 views
  • 19 Feb, 2024
  • 2 locations
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts the body and is PD-L1-negative. The names of the study interventions involved in this study are: Sacituzumab govitecan (IMMU-132) Pembrolizumab (Keytruda; MK-3475)

oophorectomy
copper
invasive breast cancer
immunostimulant
neutrophil count
  • 8 views
  • 19 Feb, 2024
  • 1 location
Fajer_Naqeeb_Prediction Model for the Risk of Developing Foot Ulcers in Diabetes.  

Introduction Foot ulcers in diabetes mellitus (DM) are a common and serious complication that can lead to infection, amputation, and increased mortality. Early identification of patients at high risk is crucial in order to implement preventive measures at an early stage. The number of people with DM is increasing globally, …

  • 0 views
  • 27 Apr, 2026
  • 2 locations
A Study to Explore Personalized Treatment for Patients with Recurrent Gynecological Malignancies Based on MTB (RWS-MTB)

Attending physicians will determine the final treatment plan, integrating multidisciplinary recommendations with patient preferences, comorbidity considerations, drug toxicity assessments, insurance coverage for off-label medications, and the availability of investigational drug trials. This arm aims to observe and evaluate the clinical efficacy of personalized treatment plans developed through molecular tumor profiling …

  • 0 views
  • 17 Jan, 2025
  • 1 location